ASH 2024 Showcases Real-World Data Demonstrating Efficacy of Ruxolitinib Across Multiple Conditions
Two posters presented at the 2024 American Society of Hematology meeting bolster evidence supporting the long-term clinical benefits of ruxolitinib for polycythemia vera and chronic graft-vs-host disease.
The Silver Lining: Progress and Promise in Combating STIs
With new CDC data expressing optimism about the epidemic of sexually transmitted infections (STIs), take a look at the current novel approaches in STI care and learn about crucial next steps to combat this public health issue.
Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines
With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.
Diverse Offerings Inspiring Meaningful Change: A Preview of AHA 2024
Rebekah Walker, PhD, a first-time participant from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, shares the offerings and opportunities at the 2024 American Heart Association (AHA) meeting that excited her and her team.
New Research Suggest Benefits of Telehealth BCBT for Treating Suicidal Thoughts, Mitigating Attempts
Researchers evaluated the lesser-known impact of telehealth treatments, including brief cognitive behavioral therapy (BCBT), to address the needs of individuals at risk of or recovering from suicidal ideation.